Inhibrx Biosciences (INBX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $90.50, +6.15% vs the prior close of $85.26.
- Volume 226.40K shares, 0.8x its 50-day average.
- New SEC filings: 4 (Oct 14, 2026).
- No new insider buys or sales reported since the prior session.
INBX jumps 6.1% to $90.50. Closed at $90.50, +6.15% vs the prior close of $85.26. Day range $87.20–$91.68, opened at $87.60.
INBX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — INBX jumps 6.1% to $90.50
- Closed at $90.50, +6.15% vs the prior close of $85.26. Day range $87.20–$91.68, opened at $87.60.
- Volume was 226.40K shares, 0.8x its 50-day average of 298.69K.
- Price is -12.7% vs its 50-day average ($103.63) and -1.1% vs its 200-day average ($91.48).
- 52-week range $28.16–$155.29; today's close sits at 49% of that range, 41.7% below the 52-week high.
Oct 14, 2026 — INBX dips 2.1% to $85.26, a 1-month low, 3 down days in a row
- Closed at $85.26, -2.09% vs the prior close of $87.08. Day range $83.61–$87.36, opened at $86.23.
- Volume was 246.10K shares, 0.8x its 50-day average of 298.12K.
- Price is -17.6% vs its 50-day average ($103.50) and -6.7% vs its 200-day average ($91.42).
- 52-week range $28.16–$155.29; today's close sits at 45% of that range, 45.1% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — INBX slides 3.8% to $87.08, a 1-month low
- Closed at $87.08, -3.81% vs the prior close of $90.53. Day range $85.79–$92.46, opened at $90.11.
- Volume was 271.30K shares, 0.9x its 50-day average of 295.39K.
- Price is -15.8% vs its 50-day average ($103.46) and -4.7% vs its 200-day average ($91.39).
- 52-week range $28.16–$155.29; today's close sits at 46% of that range, 43.9% below the 52-week high.
Oct 12, 2026 — INBX slides 4.7% to $90.53, a 1-month low
- Closed at $90.53, -4.72% vs the prior close of $95.01. Day range $90.00–$96.10, opened at $94.03.
- Volume was 216.10K shares, 0.7x its 50-day average of 293.25K.
- Price is -12.4% vs its 50-day average ($103.38) and -0.9% vs its 200-day average ($91.36).
- 52-week range $28.16–$155.29; today's close sits at 49% of that range, 41.7% below the 52-week high.
Oct 9, 2026 — INBX rises 2.4% to $95.01
- Closed at $95.01, +2.43% vs the prior close of $92.76. Day range $92.70–$95.81, opened at $92.70.
- Volume was 86.80K shares, 0.3x its 50-day average of 297.02K — lighter than usual.
- Price is -7.9% vs its 50-day average ($103.21) and +4.1% vs its 200-day average ($91.30).
- 52-week range $28.16–$155.29; today's close sits at 53% of that range, 38.8% below the 52-week high.
Oct 8, 2026 — INBX dips 0.6% to $92.76, a 1-month low, 7 down days in a row
- Closed at $92.76, -0.64% vs the prior close of $93.36. Day range $90.15–$93.28, opened at $93.14.
- Volume was 208.00K shares, 0.7x its 50-day average of 297.14K.
- Price is -9.9% vs its 50-day average ($103.00) and +1.6% vs its 200-day average ($91.26).
- 52-week range $28.16–$155.29; today's close sits at 51% of that range, 40.3% below the 52-week high.
- That makes 7 straight losses.
Oct 7, 2026 — INBX ends flat (-0.1%) to $93.36, a 1-month low, 6 down days in a row
- Closed at $93.36, -0.05% vs the prior close of $93.41. Day range $90.66–$96.71, opened at $92.02.
- Volume was 223.80K shares, 0.8x its 50-day average of 296.39K.
- Price is -9.1% vs its 50-day average ($102.73) and +2.3% vs its 200-day average ($91.23).
- 52-week range $28.16–$155.29; today's close sits at 51% of that range, 39.9% below the 52-week high.
- That makes 6 straight losses.
Oct 6, 2026 — INBX dips 1.2% to $93.41, a 1-month low, 5 down days in a row
- Closed at $93.41, -1.22% vs the prior close of $94.56. Day range $92.60–$96.96, opened at $95.52.
- Volume was 169.40K shares, 0.6x its 50-day average of 298.32K — lighter than usual.
- Price is -8.8% vs its 50-day average ($102.46) and +2.4% vs its 200-day average ($91.19).
- 52-week range $28.16–$155.29; today's close sits at 51% of that range, 39.8% below the 52-week high.
- That makes 5 straight losses.
Oct 5, 2026 — INBX dips 2.5% to $94.56, a 1-month low, 4 down days in a row
- Closed at $94.56, -2.51% vs the prior close of $96.99. Day range $94.18–$98.50, opened at $97.56.
- Volume was 206.90K shares, 0.7x its 50-day average of 297.47K.
- Price is -7.5% vs its 50-day average ($102.24) and +3.8% vs its 200-day average ($91.14).
- 52-week range $28.16–$155.29; today's close sits at 52% of that range, 39.1% below the 52-week high.
- That makes 4 straight losses.
Oct 2, 2026 — INBX dips 1.0% to $96.99, a 1-month low, 3 down days in a row
- Closed at $96.99, -0.96% vs the prior close of $97.93. Day range $96.07–$100.12, opened at $99.30.
- Volume was 201.40K shares, 0.7x its 50-day average of 296.76K.
- Price is -4.9% vs its 50-day average ($101.98) and +6.5% vs its 200-day average ($91.07).
- 52-week range $28.16–$155.29; today's close sits at 54% of that range, 37.5% below the 52-week high.
- That makes 3 straight losses.
INBX latest news & SEC filings
Every SEC filing by or about INBX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lappe Mark bought 2,470 shares at $84.07 (≈$207.65K) on Oct 14, 2026; now holds 743,018
- Lappe Mark bought 2,470 shares at $85.00 (≈$209.95K) on Oct 14, 2026; now holds 745,488
- Lappe Mark bought 100 shares at $85.76 (≈$8.58K) on Oct 14, 2026; now holds 745,588
- Lappe Mark bought 2,449 shares at $84.07 (≈$205.89K) on Oct 14, 2026; now holds 167,449
- Lappe Mark bought 2,451 shares at $85.00 (≈$208.33K) on Oct 14, 2026; now holds 169,900
- Lappe Mark bought 100 shares at $85.76 (≈$8.58K) on Oct 14, 2026; now holds 170,000
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lappe Mark bought 3,324 shares at $98.87 (≈$328.63K) on Sep 25, 2026; now holds 733,872
- Lappe Mark bought 2,176 shares at $99.60 (≈$216.73K) on Sep 25, 2026; now holds 736,048
- Lappe Mark bought 1,500 shares at $98.88 (≈$148.32K) on Sep 28, 2026; now holds 737,548
- Lappe Mark bought 3,000 shares at $101.70 (≈$305.11K) on Sep 28, 2026; now holds 740,548
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kayyem Jon Faiz bought 5,000 shares at $100.00 (≈$500.00K) on Sep 23, 2026; now holds 434,360
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 18, 2026 · Form 4/A — Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 18, 2026 · Form 4/A — Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 18, 2026 · Form 4/A — Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $1.30M) (-100.0% vs Jun 30, 2025)
- Net income: -$36.65M (prior year -$28.65M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$2.34 (prior year -$1.85) (loss widened vs Jun 30, 2025)
Aug 3, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 3.02 — Sold unregistered shares.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade INBX
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 14, 2026, Mar 19, 2026, Nov 14, 2025. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.74% (largest 9.3%).
- Liquidity: about 246.78K shares (≈$22.33M) trade per day on average.
- 52-week position: $90.50 vs a range of $28.16–$155.29 (49% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 14 open-market buys, 11 sales; latest: Mark Lappe bought 1,500 shares on Sep 28, 2026.
- Latest filings: 8-K Sep 28, 2026; 8-K Sep 8, 2026; 8-K Aug 13, 2026.
- Share count: 14.72M shares outstanding (Aug 7, 2026), +1.6% vs a year earlier.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
INBX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 87.60 | 91.68 | 87.20 | 90.50 | 226.40K |
| Oct 14, 2026 | 86.23 | 87.36 | 83.61 | 85.26 | 246.10K |
| Oct 13, 2026 | 90.11 | 92.46 | 85.79 | 87.08 | 271.30K |
| Oct 12, 2026 | 94.03 | 96.10 | 90.00 | 90.53 | 216.10K |
| Oct 9, 2026 | 92.70 | 95.81 | 92.70 | 95.01 | 86.80K |
| Oct 8, 2026 | 93.14 | 93.28 | 90.15 | 92.76 | 208.00K |
| Oct 7, 2026 | 92.02 | 96.71 | 90.66 | 93.36 | 223.80K |
| Oct 6, 2026 | 95.52 | 96.96 | 92.60 | 93.41 | 169.40K |
| Oct 5, 2026 | 97.56 | 98.50 | 94.18 | 94.56 | 206.90K |
| Oct 2, 2026 | 99.30 | 100.12 | 96.07 | 96.99 | 201.40K |
| Oct 1, 2026 | 100.71 | 102.16 | 97.58 | 97.93 | 216.60K |
| Sep 30, 2026 | 105.67 | 106.94 | 100.08 | 100.08 | 389.50K |
| Sep 29, 2026 | 105.31 | 107.90 | 102.51 | 104.83 | 240.90K |
| Sep 28, 2026 | 98.69 | 104.55 | 98.51 | 101.71 | 188.10K |
| Sep 25, 2026 | 101.29 | 101.29 | 98.09 | 99.61 | 158.70K |
| Sep 24, 2026 | 102.38 | 104.49 | 99.53 | 100.40 | 285.70K |
| Sep 23, 2026 | 110.12 | 110.88 | 98.56 | 100.33 | 375.30K |
| Sep 22, 2026 | 112.45 | 117.14 | 109.05 | 110.67 | 292.10K |
| Sep 21, 2026 | 112.69 | 113.18 | 108.94 | 112.04 | 249.10K |
| Sep 18, 2026 | 106.45 | 110.41 | 105.04 | 109.35 | 483.40K |
About Inhibrx Biosciences
Inhibrx Biosciences (INBX) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in LA JOLLA, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 2007919.
INBX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Douglas Forsyth | Director | Sep 18, 2026 |
| Jon Faiz Kayyem | Director | Sep 23, 2026 |
| Mark Lappe | Chief Executive Officer | Sep 28, 2026 |
| Kimberly Manhard | Director | Sep 18, 2026 |
| Kristiina Md Vuori | Director | Sep 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Mark Lappe | Chief Executive Officer | Sep 28, 2026 |
| David Matly | President | Apr 27, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 28, 2026 | Mark Lappe | Buy | 1,500 | $98.88 |
| Sep 28, 2026 | Mark Lappe | Buy | 3,000 | $101.70 |
| Sep 25, 2026 | Mark Lappe | Buy | 3,324 | $98.87 |
| Sep 25, 2026 | Mark Lappe | Buy | 2,176 | $99.60 |
| Sep 23, 2026 | Jon Faiz Kayyem | Buy | 5,000 | $100.00 |
| Sep 16, 2026 | Jon Faiz Kayyem | Buy | 5,000 | $100.00 |
| Sep 15, 2026 | Kimberly Manhard | Sale | 500 | $105.05 |
| Sep 14, 2026 | Kimberly Manhard | Sale | 500 | $110.26 |
| Sep 11, 2026 | Kimberly Manhard | Sale | 500 | $111.78 |
| Sep 9, 2026 | Kimberly Manhard | Sale | 500 | $115.80 |
| Sep 8, 2026 | Kimberly Manhard | Sale | 500 | $115.14 |
| Sep 8, 2026 | Jon Faiz Kayyem | Buy | 5,000 | $113.52 |
| Sep 8, 2026 | Mark Lappe | Buy | 500 | $108.24 |
| Sep 8, 2026 | Mark Lappe | Buy | 9,681 | $112.28 |
| Sep 8, 2026 | Mark Lappe | Buy | 1,219 | $111.88 |
INBX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $1.30M | $-140.06M | -9.04 | $-129.79M |
| Dec 31, 2024 | $200.00K | $1.69B | 112.62 | $-194.41M |
| Dec 31, 2023 | $1.80M | $-241.36M | -20.48 | $-193.31M |
Latest balance sheet: total assets $154.22M, total liabilities $207.20M, cash $133.34M (as of Jun 30, 2026).
INBX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $97.01 |
| May 14, 2026 | 8-K Item 2.02 (results) | $116.16 |
| Mar 19, 2026 | 8-K Item 2.02 (results) | $64.87 |
| Nov 14, 2025 | 8-K Item 2.02 (results) | $79.13 |
| Aug 13, 2025 | 8-K Item 2.02 (results) | $23.57 |
| May 14, 2025 | 8-K Item 2.02 (results) | $10.84 |
| Mar 17, 2025 | 8-K Item 2.02 (results) | $13.94 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $14.33 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on INBX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.